Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 01

655P - Toxicity and efficacy of antibody drug conjugates (ADC) in advanced solid tumors: A pooled analysis of Sarah Cannon UK

Date

14 Sep 2024

Session

Poster session 01

Topics

Clinical Research;  Cytotoxic Therapy;  Targeted Therapy

Tumour Site

Presenters

Rachel Woodford

Citation

Annals of Oncology (2024) 35 (suppl_2): S482-S535. 10.1016/annonc/annonc1589

Authors

R. Woodford1, N. Beygozlu2, A. Cammarota3, K. Joshi4, R.M. Grochot5, A. Williams6, E. Fontana7

Author affiliations

  • 1 Medical Oncology Department, Sarah Cannon Research Institute SCRI UK, W1G 6AD - London/GB
  • 2 Science And Technology, UCL - University College London, WC1E 6BT - London/GB
  • 3 Medical Oncology Department, Humanitas University, 20090 - Milan/IT
  • 4 London, Sarah Cannon Research Institute SCRI UK, W1G 6AD - London/GB
  • 5 Drug Development Unit, Sarah Cannon Research Institute SCRI UK, W1G 6AD - London/GB
  • 6 Medical Oncology, Sarah Cannon Research Institute SCRI UK, W1G 6AD - London/GB
  • 7 Drug Development, Sarah Cannon Research Institute SCRI UK, W1G 6AD - London/GB

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 655P

Background

ADCs are a rapidly emerging modality of systemic anti-cancer treatment with 11 agents FDA approved and more under investigation.

Methods

Patients that received at least 1 dose of ADC in phase 1-3 trials at SCRI UK between 2012-2023 were included. Patient and tumor characteristics, toxicity and outcomes overall and for subgroups of interest were assessed using descriptive statistics and cox regression.

Results

102 patients from 16 trials (8 phase 1, 8 phase 2-3) of 13 different ADCs were included (median age 62 (32-81), male 32.4%). Main tumor types were breast (n=40, 38.5%) and gynecological (n=19, 18.3%). Median number of prior treatment lines was 3 (1-18). Payloads comprised alkylating agents (AA, n=3), microtubule inhibitors (MTI, n=8) or a topoisomerase inhibitor (Topo-I, n=2). 3 ADCs targeted an oncogene (HER2) vs tumor associated antigens (TAA). TRAEs of any grade occurred in 88% of patients (grade 3-4 25%). Colitis occurred in 3.8% (2.9%), ILD 3.8% (1.0%), neuropathy 26.0% (0%), eye toxicity 22.1% (0%) and hepatotoxicity 27.8% (4.8%). Most toxicities occurred early (

Conclusions

ADC activity is seen across different tumors with higher efficacy when oncogene targeted. Identification of timelines of expected toxicities is critical for clinical management and mitigation strategies.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

R. Woodford, A. Cammarota, K. Joshi, R.M. Grochot: Financial Interests, Institutional, Full or part-time Employment: HCA International. A. Williams: Financial Interests, Institutional, Full or part-time Employment: HCA International; Financial Interests, Personal, Advisory Role: Ellipses Pharma UK. E. Fontana: Financial Interests, Personal, Invited Speaker: Caris Life Science, Repair Therapeutics; Financial Interests, Personal, Other, Conference attendance: Sapience Pharma; Financial Interests, Personal, Invited Speaker, Conference Attendance: Bicycles Therapeutics; Financial Interests, Personal, Full or part-time Employment: Hospital Corporation of America (HCA) International; Financial Interests, Personal, Officer: EORTC; Financial Interests, Institutional, Coordinating PI: Repair Therapeutics, Amgen, Taiho Pharmaceutical; Financial Interests, Institutional, Local PI: Bicycle Therapeutics, Artios Pharma, Seagen, Nurix Therapeutics, BioNTech SE, Relay Therapeutics, Pfizer, Roche, Daiichi Sankyo, Gilead Science, Basilea Pharmaceutica, Jiangsu Hengrui Medicine, Mereo Biopharma, Hutchmed, Merus, Crescendo Biologics, GSK plc, BeiGene, Turning Point Therapeutics, Sapience Pharma, Arcus Bioscience, Exelixis, Nerviano Medica, Elipsees, Deciphera, Ribon Therapeutics. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.